home / stock / allk / allk quote
Last: | $0.9052 |
---|---|
Change Percent: | 0.11% |
Open: | $0.9141 |
Close: | $0.9052 |
High: | $0.96 |
Low: | $0.8702 |
Volume: | 560,516 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.9052 | $0.9141 | $0.9052 | $0.96 | $0.8702 | 560,516 | 07-29-2024 |
$0.9151 | $0.8797 | $0.9151 | $0.9151 | $0.8699 | 207,648 | 07-26-2024 |
$0.865 | $0.87 | $0.865 | $0.9466 | $0.8545 | 596,912 | 07-25-2024 |
$0.8797 | $0.84 | $0.8797 | $0.8797 | $0.8251 | 564,926 | 07-24-2024 |
$0.85 | $0.76 | $0.85 | $0.87 | $0.76 | 913,959 | 07-23-2024 |
$0.7539 | $0.69 | $0.7539 | $0.7545 | $0.675 | 335,480 | 07-22-2024 |
$0.6892 | $0.75 | $0.6892 | $0.7954 | $0.6856 | 351,133 | 07-19-2024 |
$0.75 | $0.81 | $0.75 | $0.8234 | $0.75 | 269,726 | 07-18-2024 |
$0.8235 | $0.8411 | $0.8235 | $0.875 | $0.804 | 280,262 | 07-17-2024 |
$0.8395 | $0.87 | $0.8395 | $0.8903 | $0.831 | 415,336 | 07-16-2024 |
$0.863 | $0.9 | $0.863 | $0.9071 | $0.851 | 510,668 | 07-15-2024 |
$0.8603 | $0.8816 | $0.8603 | $0.8899 | $0.8308 | 260,298 | 07-12-2024 |
$0.8818 | $0.831 | $0.8818 | $0.8897 | $0.831 | 640,415 | 07-11-2024 |
$0.83 | $0.82 | $0.83 | $0.84 | $0.817 | 173,888 | 07-10-2024 |
$0.8163 | $0.796 | $0.8163 | $0.83 | $0.77 | 265,702 | 07-09-2024 |
$0.7666 | $0.74 | $0.7666 | $0.796 | $0.73 | 454,359 | 07-08-2024 |
$0.7323 | $0.765 | $0.7323 | $0.77765 | $0.72 | 681,709 | 07-05-2024 |
$0.76 | $0.8624 | $0.76 | $0.8799 | $0.76 | 502,389 | 07-04-2024 |
$0.76 | $0.8624 | $0.76 | $0.8799 | $0.76 | 502,389 | 07-03-2024 |
$0.8406 | $0.89 | $0.8406 | $0.932 | $0.8334 | 758,632 | 07-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...